The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
ApexOnco Front Page
Recent articles
Parabilis’s zolucatetide bids to be third to a rather small market.
ABO2109 and ODI-2001 are starting their first human studies.
Relapsed biliary tract cancer, and ASCO, beckon.
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
A Libtayo combo fails to beat Keytruda in first-line melanoma.
Golcadomide and iberdomide are set to feature at EHA.
